RSS

AstraZeneca

Contract development manufacturing organisation (CDMO) Lonza is expanding its highly potent API (HPAPI) capacity in order to meet increased market demand. Read more

News

The Centre for Process Innovation has announced a collaboration with major pharma players GSK and AstraZeneca to create a continuous wet granulation manufacturing facility for oral solid dosage pharmaceuticals. Read more

News

A major deal has been struck between pharma players AstraZeneca and Daiichi Sankyo to develop and market a potentially transformative cancer medicine. Read more

News

Major pharma player AstraZeneca is to cut almost 100 jobs in what’s being described as a ‘hammer blow’ to UK manufacturing. Read more

News

Biotechnology company Aptamer Group is collaborating with AstraZeneca to develop drug delivery devices targeting the kidney. Read more

News

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca’s Tagrisso (osimertinib) as a first-line treatment of patients with inoperable or recurrent epidermal growth factor mutation-positive non-small cell lung cancer Read more

News

Data has been presented by AstraZeneca and Merck demonstrating clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care Read more

News

AstraZeneca and its global biologics research and development arm, MedImmune, have announced positive overall survival (OS) results of the Phase III PACIFIC trial evaluating Imfinzi (durvalumab) for the treatment of unresectable stage III NSCL Read more

News

Privately-held company, Emulate, and the Innovative Medicines and Early Development Biotech Unit of pharmaceutical company AstraZeneca have formed a collaborative partnership to develop and embed organ-on-chips technology into laboratory research Read more

News

The European Medicines Agency (EMA) has approved AstraZeneca and Merck’s Lynparza (olaparib) tablets as maintenance therapy for the treatment of platinum-sensitive relapsed ovarian cancer, regardless of BRCA status. Read more

News

A positive opinion has been adopted by the CHMP of the European Medicines Agency, recommending a change to the terms of the marketing authorisation for AstraZeneca’s Tagrisso (osimertinib) to include first-line treatment. Read more

News

Diagnostics company, Owlstone Medical, has signed a service agreement with global biopharmaceutical company, AstraZeneca, to explore how breath can be used to identify novel biomarkers for personalised medicine applications. Read more

News

Karolinska Institute spin out company, Pelago Bioscience, has entered into a strategic research collaboration and licence agreement with AstraZeneca for the further advancement of the CETSA method and its use in pre-clinical discovery Read more

News

The US FDA has expanded its approval of Imfinzi (durvalumab) to now include the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumours are unresectable and have not progressed after chemoradiation treatment. Read more

News

The collaboration between AstraZeneca and TissUse is progressing with the establishment of relevant microphysiological system (MPS) models based on TissUse’s multi-organ-chip technology, the companies announced. Read more

Technology

A ceremony has been held in Sweden marking the start of a long-term manufacturing agreement between Cambrex — manufacturer of small molecule innovator and active pharmaceutical ingredients — and AstraZeneca. Read more

News

Researchers from Cardiff University, in collaboration with Liverpool John Moores University and AstraZeneca, have developed a new tool to assess the likelihood of a drug undergoing racemisation once inside the body. Read more

Technology

Alderley Park has been confirmed as the interim home for the Cancer Research UK (CRUK) Manchester Institute, underlining it as a key asset in the North of England. Read more

News

The US Food and Drug Administration (FDA) has accepted and granted priority review of a supplemental new drug application (sNDA) for Lynparza to be used in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer. Read more

News

The House of Lords Science and Technology Committee will hear evidence from pharmaceutical companies, including AstraZeneca and GlaxoSmithKline (GSK), this week in its continued inquiry into the life sciences and industrial strategy. Read more

News